The capital injection will accelerate Element Biosciences’ efforts to scale its genomic ecosystem, expand its global footprint, and refine its product roadmap. Samsung’s decision to increase its stake highlights a strategic pivot toward precision medicine, with the tech giant citing confidence in Element’s advancements in next-generation sequencing and integrated biological data workflows.

Wayne H. Elowe, co-chair of Greenberg Traurig’s Global Life Sciences & Medical Technology Group, led the legal team through the complex transaction. The firm utilized its multidisciplinary platform to navigate intellectual property, regulatory, and antitrust considerations across international offices, including teams in Seoul, Singapore, and the United States. The transaction remains subject to customary regulatory approvals.